SCHEMBL30679042

SCHEMBL30679042

CN1CCN(c2cc(O)c([N+](=O)[O-])cc2F)CC1

nearest known ligand 0.71

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.71
ALDH1A1 P00352 6/20 0.71
SMN1; SMN2 Q16637 2/20 0.71
CYP1A2 P05177 1/20 0.71
CYP2D6 P10635 1/20 0.71
CYP2C9 P11712 1/20 0.71
CYP2C19 P33261 1/20 0.71
LMNA P02545 4/20 0.69
GAA P10253 1/20 0.62
SIRT6 Q8N6T7 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
GPR174 Q9BXC1 3/20 0.53
PKM P14618 1/20 0.52
MAPK1 P28482 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29847854 0.87 MAPT (0.76) MAPTALDH1A1SMN1; SMN2CYP1A2CYP2D6
SCHEMBL16513593 0.87 MAPT (0.76) MAPTALDH1A1SMN1; SMN2CYP1A2CYP2D6
SCHEMBL23525556 0.83 MAPT (0.58) MAPTALDH1A1SMN1; SMN2CYP1A2CYP2D6
SCHEMBL22652238 0.83 MAPT (0.76) MAPTALDH1A1SMN1; SMN2CYP1A2CYP2D6
SCHEMBL3925665 0.83 MAPT (0.71) MAPTALDH1A1SMN1; SMN2CYP1A2CYP2D6
SCHEMBL4365700 0.82 MAPT (0.66) MAPTALDH1A1SMN1; SMN2CYP1A2CYP2D6
SCHEMBL23525546 0.82 MAPT (0.51) MAPTALDH1A1SMN1; SMN2CYP1A2CYP2D6
SCHEMBL30020102 0.82 MAPT (0.69) MAPTALDH1A1SMN1; SMN2CYP1A2CYP2D6
SCHEMBL23293826 0.81 MAPT (0.67) MAPTALDH1A1SMN1; SMN2CYP1A2CYP2D6
SCHEMBL8221482 0.80 MAPT (0.60) MAPTALDH1A1SMN1; SMN2CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116981664-A Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of NUAK kinase, compositions and uses thereof 安大略省癌症研究所(OICR) 2023-10-31 CN disclosed